6.1.2. seminoma germ cell tumour clinical stage i. 20% cs sgct patients subclinical metastatic disease, usually retroperitoneum, relapse orchidectomy alone . adjuvant treatment decisions based thorough discussions patient, incorporating potential risks benefits, well individual patient circumstances, 80% unselected cs sgct patients cured orchidectomy alone. regardless management, survival cs disease almost 100% . 6.1.2.1. surveillance requires strict protocol repeated cross-sectional imaging, monitoring serum tumour markers clinical assessment early identification patients experiencing relapse must receive salvage treatment (see table 11). several prospective, non-randomised surveillance studies conducted past decade. shown overall risk relapse unselected cs patients 12-20% five years 17% largest series 1,500 patients . occur retroperitoneum first two years . according sr, active surveillance offers almost identical overall survival adjuvant management strategies, approaching 100% . cancer-specific survival (css) rate “active surveillance” (as) cs seminoma 99% . whilst cost effective compared management strategies , surveillance represent burden patient due need repeated imaging retroperitoneum clinic visits. may negatively impact patient compliance crucial active surveillance strategy. 6.1.2.2. adjuvant chemotherapy rct comparing one cycle carboplatin reaching area curve 7 mg/ml/min (auc 7) adjuvant radiotherapy (rt) showed difference relapse-free rates (95% 96%), time recurrence survival median follow-up four years . adjuvant carboplatin (auc 7) therefore alternative rt surveillance cs sgct . time relapse carboplatin may longer as, retrospective data reported median time relapse nineteen months, 15% relapses occurring beyond three years. patients relapsing adjuvant carboplatin successfully treated standard, stage-adapted cisplatin-based chemotherapy . selected cases, retroperitoneal lymph-node dissection may adopted specific protocols (see below). one cycle adjuvant carboplatin seem significant long-term toxicities. series 199 cs sgct patients, increase overall mortality, mortality cardiovascular events excess haematological non-testicular solid malignancies compared general population uk . 6.1.2.3. adjuvant radiotherapy radiotherapy generally reserved highly selective group patients, would unsuitable systemic chemotherapy event relapse. relates toxicity rt, specifically long-term risk non-germ cell malignancies radiation field [111-114]. generally, adjuvant rt avoided, particularly young patients long life expectancy. risk-adapted treatment prospective trials based tumour size > 4 cm stromal rete testis invasion demonstrated feasibility risk-adapted approach [33-36,115]. trial 897 patients offered surveillance patients one two risk factors whilst patients risk factors offered one dose carboplatin, auc 7 . median follow-up 5.6 years, patients without risk factors, 4% surveillance relapsed compared 2% adjuvant carboplatin. one risk factors 15.5% surveillance patients relapsed vs. 9% receiving adjuvant carboplatin. thirty-three per cent relapses adjuvant carboplatin occurred three years orchidectomy 3% occurring five years . 6.1.2.4. summary evidence recommendations treatment clinical stage seminoma germ cell tumour testis summary evidencelepatients cs sgct have, general, low risk recurrence2aa combination tumour size category rete testis invasion correlate risk relapse 5 years.2aevidence ease use limited routine use guiding adjuvant treatment decisions upon risk factors.2aactive surveillance feasible approach conditional relapse risk unselected series 12-20%. disease-free survival approaches 100% independently treatment.2ain patients without conventional risk factors (tumour size < 4 cm rete testis invasion), five-year relapse rate surveillance 6-8%, respectively; whereas presence one two risk factors, five-year relapse rate contemporary surveillance series 15-20%.2bin non-randomised prospective series five-year relapse rates adjuvant carboplatin 2% patients without conventional risk factors 9% patients one risk factors.2badjuvant chemotherapy one course carboplatin auc 7 inferior adjuvant radiotherapy pathological risk factors considered. relapse rates adjuvant treatments around 5%.1badjuvant radiotherapy associated increased risk developing secondary non-germ cell malignancies.2b recommendationsstrength ratingfully inform patient available management options, including surveillance adjuvant therapy orchidectomy, well treatment-specific recurrence rates acute long-term side effects.strongoffer surveillance preferred management option resources available patient compliant.strongoffer one dose carboplatin area curve 7 adjuvant chemotherapy considered.strongdo perform adjuvant treatment patients low risk recurrence (no risk factors).strongdo routinely perform adjuvant radiotherapy.strongadjuvant radiotherapy reserved highly selected patients suitable surveillance contraindication chemotherapy.strong